SYK

Stryker has gained 3.8% since March-end as Mako robotics, hospital capital demand and international growth drive momentum.

Stryker's stronger growth, margin gains and product pipeline support the case, but cyber costs, supply constraints and acquisition execution keep risks elevated.

Stryker enters the second half with Q2 momentum restored, but meeting guidance hinges on production, backlog conversion and managing cyber and supply risks.

Stryker's 13.6% three-month rally reflects stronger sales, margins and production, but execution risks and a premium peer valuation could test further gains.

Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?

Portage, Michigan, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders of record at the close of business on June 30, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter.

Stryker tops Q2 estimates as sales regain momentum after a cyber disruption, but narrowed 2026 guidance weighs on shares, sending them down 7.8% in after-hours trading.

Stryker Corporation (SYK) Q2 2026 Earnings Call Transcript

U.S. medical device maker Stryker on Thursday beat Wall Street estimates for second-quarter results, aided by ​strong demand for its implants and devices ‌used in complex procedures ranging from spinal to orthopedic surgeries.

The medical technology company reported a profit of $1.28 billion and and said it has made progress in recovering from a March cyberattack.